The molecular basis of herpesviruses as oncolytic agents

Current Pharmaceutical Biotechnology

Volumn 13, Issue 9, 2012, Pages 1795-1803

  Menotti, Laura ^a   Campadelli Fiume, Gabriella ^a   Nanni, Patrizia ^a   Lollini, Pier Luigi ^a   de Giovanni, Carla ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

1 34.5; Glioma; Her 2; Herpes simplex virus; Oncolytic virotherapy; Oncolytic virus

Indexed keywords

ACICLOVIR; LIGAND; ONCOLYTIC HERPES VIRUS; VIRUS ENVELOPE PROTEIN;

ARTICLE; DNA MODIFICATION; DRUG RESEARCH; DRUG SPECIFICITY; GENE DELETION; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS; HERPES VIRUS INFECTION; HUMAN; INFECTION CONTROL; NONHUMAN; TUMOR CELL DESTRUCTION; VIRAL GENETICS; VIRAL TROPISM; VIRUS GENE; VIRUS GENOME; VIRUS RECOMBINANT;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SIMPLEXVIRUS;

SIMPLEXVIRUS;

EID: 84863558325     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800958931     Document Type: Article

References (71)

1. He, B.; Gross, M.; Roizman, B. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci U S A, 1997, 94, 843-848.
2. Andreansky, S.; Soroceanu, L.; Flotte, E.R.; Chou, J.; Markert, J.M.; Gillespie, G.Y.; Roizman, B.; Whitley, R.J. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res, 1997, 57, 1502-1509.
3. Chung, S.M.; Advani, S.J.; Bradley, J.D.; Kataoka, Y.; Vashistha, K.; Yan, S.Y.; Markert, J.M.; Gillespie, G.Y.; Whitley, R.J.; Roizman, B.; Weichselbaum, R.R. The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther, 2002, 9, 75-80.
4. Smith, K.D.; Mezhir, J.J.; Bickenbach, K.; Veerapong, J.; Charron, J.; Posner, M.C.; Roizman, B.; Weichselbaum, R.R. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol, 2006, 80, 1110-1120.
5. Veerapong, J.; Bickenbach, K.A.; Shao, M.Y.; Smith, K.D.; Posner, M.C.; Roizman, B.; Weichselbaum, R.R. Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res, 2007, 67, 8301-8306.
6. Kolodkin-Gal, D.; Edden, Y.; Hartshtark, Z.; Ilan, L.; Khalaileh, A.; Pikarsky, A.J.; Pikarsky, E.; Rabkin, S.D.; Panet, A.; Zamir, G. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect. Gene Ther, 2009, 16, 905-915.
7. Shah, A.C.; Parker, J.N.; Gillespie, G.Y.; Lakeman, F.D.; Meleth, S.; Markert, J.M.; Cassady, K.A. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Ther, 2007, 14, 1045-1054.
8. Zhou, G.; Ye, G.J.; Debinski, W.; Roizman, B. Engineered herpes simplex virus 1 is dependent on IL13Ralpha2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 15124-15129.
9. Campadelli-Fiume, G.; Amasio, M.; Avitabile, E.; Cerretani, A.; Forghieri, C.; Gianni, T.; Menotti, L. The multipartite system that mediates entry of herpes simplex virus into the cell. Rev Med Virol, 2007, 17, 313-326.
10. Avitabile, E.; Forghieri, C.; Campadelli-Fiume, G. Complexes between Herpes Simplex Virus Glycoproteins gD, gB, and gH Detected in Cells by Complementation of Split Enhanced Green Fluorescent Protein. J Virol, 2007, 81, 11532-11537.
11. Avitabile, E.; Forghieri, C.; Campadelli-Fiume, G. Cross talk among the glycoproteins involved in herpes simplex virus entry and fusion: the interaction between gB and gH/gL does not necessarily require gD. J Virol, 2009, 83, 10752-10760.
12. Heldwein, E.E.; Lou, H.; Bender, F.C.; Cohen, G.H.; Eisenberg, R.J.; Harrison, S.C. Crystal structure of glycoprotein B from herpes simplex virus 1. Science, 2006, 313, 217-220.
13. Zhou, G.; Roizman, B. Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells. J Virol, 2005, 79, 5272-5277.
14. Debinski, W. An immune regulatory cytokine receptor and glioblastoma multiforme: an unexpected link. Crit Rev Oncog, 1998, 9, 255-268.
15. Debinski, W.; Gibo, D.M. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/ testis antigen. Mol Med, 2000, 6, 440-449.
16. Gladson, C.L.; Pijuan-Thompson, V.; Olman, M.A.; Gillespie, G.Y.; Yacoub, I.Z. Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am J Pathol, 1995, 146, 1150-1160.
17. Yamamoto, M.; Sawaya, R.; Mohanam, S.; Rao, V.H.; Bruner, J.M.; Nicolson, G.L.; Rao, J.S. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res, 1994, 54, 5016-5020.
18. Kamiyama, H.; Zhou, G.; Roizman, B. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor. Gene Ther, 2006, 13, 621-629.
19. Zhou, G.; Roizman, B. Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor. Proc Natl Acad Sci U S A, 2006, 103, 5508-5513.
20. Connolly, S.A.; Landsburg, D.J.; Carfi, A.; Whitbeck, C.J.; Zuo, Y.; Wiley, D.C.; Cohen, G.H.; Eisenberg, R.J. Potential nectin-1 binding site on herpes simplex virus glycoportein D. J Virol, 2005, 79, 1282-1295.
21. Manoj, S.; Jogger, C.R.; Myscofski, D.; Yoon, M.; Spear, P.G. Mutations in herpes simplex virus glycoprotein D that prevent cell entry via nectins and alter cell tropism. Proc Natl Acad Sci U S A, 2004, 101, 12414-12421.
22. Menotti, L.; Cerretani, A.; Hengel, H.; Campadelli-Fiume, G. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol, 2008, 20, 10153-10161.
23. Gonzalez-Angulo, A.M.; Hortobagyi, G.N.; Esteva, F.J. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist, 2006, 11, 857-867.
24. Holbro, T.; Hynes, N.E. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol, 2004, 44, 195-217.
25. Ross, J.S.; Fletcher, J.A.; Linette, G.P.; Stec, J.; Clark, E.; Ayers, M.; Symmans, W.F.; Pusztai, L.; Bloom, K.J. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist, 2003, 8, 307-325.
26. Hynes, N.E.; Lane, H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 2005, 5, 341-354.
27. Baselga, J.; Perez, E.A.; Pienkowski, T.; Bell, R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist, 2006, 11 Suppl 1, 4-12.
28. Lollini, P.L.; Cavallo, F.; Nanni, P.; Forni, G. Vaccines for tumour prevention. Nat Rev Cancer, 2006, 6, 204-216.
29. Nahta, R.; Yu, D.; Hung, M.C.; Hortobagyi, G.N.; Esteva, F.J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol, 2006, 3, 269-280.
30. Melisko, M.E.; Glantz, M.; Rugo, H.S. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol, 2009, 6, 25-33.
31. Bergman, I.; Griffin, J.A.; Gao, Y.; Whitaker-Dowling, P. Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu. Int J Cancer, 2007, 121, 425-430.
32. Belousova, N.; Mikheeva, G.; Gelovani, J.; Krasnykh, V. Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer. J Virol, 2008, 82, 630-637.
33. Menotti, L.; Cerretani, A.; Campadelli-Fiume, G. A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors. J Virol, 2006, 80, 5531-5539.
34. Menotti, L.; Nicoletti, G.; Gatta, V.; Croci, S.; Landuzzi, L.; De Giovanni, C.; Nanni, P.; Lollini, P.L.; Campadelli-Fiume, G. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc Natl Acad Sci USA, 2009, 106, 9039-9044.
35. Zhou, G.; Roizman, B. Separation of receptor binding and profusogenic domains of glycoprotein D of herpes simplex virus 1 into distinct interacting proteins. Proc Natl Acad Sci U S A, 2007, 104, 4142-4146.
36. Mezhir, J.J.; Advani, S.J.; Smith, K.D.; Darga, T.E.; Poon, A.P.; Schmidt, H.; Posner, M.C.; Roizman, B.; Weichselbaum, R.R. Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses. Cancer Res, 2005, 65, 9479-9484.
37. Advani, S.J.; Weichselbaum, R.R.; Chmura, S.J. Enhancing radiotherapy with genetically engineered viruses. J Clin Oncol, 2007, 25, 4090-4095.
38. Advani, S.J.; Mezhir, J.J.; Roizman, B.; Weichselbaum, R.R. Re- VOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys, 2006, 66, 637-646.
39. Kambara, H.; Okano, H.; Chiocca, E.A.; Saeki, Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res, 2005, 65, 2832-2839.
40. Mohr, I.; Gluzman, Y. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. Embo J, 1996, 15, 4759-4766.
41. Cassady, K.A.; Gross, M.; Roizman, B. The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. J Virol, 1998, 72, 7005-7011.
42. Mohr, I.; Sternberg, D.; Ward, S.; Leib, D.; Mulvey, M.; Gluzman, Y. A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol, 2001, 75, 5189-5196.
43. Todo, T.; Rabkin, S.D.; Sundaresan, P.; Wu, A.; Meehan, K.R.; Herscowitz, H.B.; Martuza, R.L. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication- competent herpes simplex virus. Hum Gene Ther, 1999, 10, 2741-2755.
44. Currier, M.A.; Gillespie, R.A.; Sawtell, N.M.; Mahller, Y.Y.; Stroup, G.; Collins, M.H.; Kambara, H.; Chiocca, E.A.; Cripe, T.P. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther, 2008, 16, 879-885.
45. Nakamura, H.; Mullen, J.T.; Chandrasekhar, S.; Pawlik, T.M.; Yoon, S.S.; Tanabe, K.K. Multimodality therapy with a replicationconditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res, 2001, 61, 5447-5452.
46. Andreansky, S.; He, B.; van Cott, J.; McGhee, J.; Markert, J.M.; Gillespie, G.Y.; Roizman, B.; Whitley, R.J. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther, 1998, 5, 121-130.
47. Wong, R.J.; Chan, M.K.; Yu, Z.; Kim, T.H.; Bhargava, A.; Stiles, B.M.; Horsburgh, B.C.; Shah, J.P.; Ghossein, R.A.; Singh, B.; Fong, Y. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res, 2004, 10, 251-259.
48. Varghese, S.; Rabkin, S.D.; Nielsen, P.G.; Wang, W.; Martuza, R.L. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin Cancer Res, 2006, 12, 2919-2927.
49. Varghese, S.; Rabkin, S.D.; Nielsen, G.P.; MacGarvey, U.; Liu, R.; Martuza, R.L. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res, 2007, 67, 9371-9379.
50. Fukuhara, H.; Ino, Y.; Kuroda, T.; Martuza, R.L.; Todo, T. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res, 2005, 65, 10663-10668.
51. Ino, Y.; Saeki, Y.; Fukuhara, H.; Todo, T. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res, 2006, 12, 643-652.
52. Han, Z.Q.; Assenberg, M.; Liu, B.L.; Wang, Y.B.; Simpson, G.; Thomas, S.; Coffin, R.S. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy. J Gene Med, 2007, 9, 99-106.
53. Liu, T.C.; Zhang, T.; Fukuhara, H.; Kuroda, T.; Todo, T.; Canron, X.; Bikfalvi, A.; Martuza, R.L.; Kurtz, A.; Rabkin, S.D. Dominantnegative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res, 2006, 12, 6791-6799.
54. Nemunaitis, J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines, 2005, 4, 259-274.
55. Varghese, S.; Rabkin, S.D.; Liu, R.; Nielsen, P.G.; Ipe, T.; Martuza, R.L. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther, 2006, 13, 253-265.
56. Hu, J.C.; Coffin, R.S.; Davis, C.J.; Graham, N.J.; Groves, N.; Guest, P.J.; Harrington, K.J.; James, N.D.; Love, C.A.; McNeish, I.; Medley, L.C.; Michael, A.; Nutting, C.M.; Pandha, H.S.; Shorrock, C.A.; Simpson, J.; Steiner, J.; Steven, N.M.; Wright, D.; Coombes, R.C. A phase I study of OncoVEXGM-CSF, a secondgeneration oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res, 2006, 12, 6737-6747.
57. Todo, T. Armed oncolytic herpes simplex viruses for brain tumor therapy. Cell Adh Migr, 2008, 2, 208-213.
58. Grandi, P.; Peruzzi, P.; Reinhart, B.; Cohen, J.B.; Chiocca, E.A.; Glorioso, J.C. Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother, 2009, 9, 505-517.
59. Parker, J.N.; Bauer, D.F.; Cody, J.J.; Markert, J.M. Oncolytic viral therapy of malignant glioma. Neurotherapeutics, 2009, 6, 558-569.
60. Rampling, R.; Cruickshank, G.; Papanastassiou, V.; Nicoll, J.; Hadley, D.; Brennan, D.; Petty, R.; MacLean, A.; Harland, J.; McKie, E.; Mabbs, R.; Brown, M. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther, 2000, 7, 859-866.
61. Papanastassiou, V.; Rampling, R.; Fraser, M.; Petty, R.; Hadley, D.; Nicoll, J.; Harland, J.; Mabbs, R.; Brown, M. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther, 2002, 9, 398-406.
62. Harrow, S.; Papanastassiou, V.; Harland, J.; Mabbs, R.; Petty, R.; Fraser, M.; Hadley, D.; Patterson, J.; Brown, S.M.; Rampling, R. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther, 2004, 11, 1648-1658.
63. Markert, J.M.; Gillespie, G.Y.; Weichselbaum, R.R.; Roizman, B.; Whitley, R.J. Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol, 2000, 10, 17-30.
64. Markert, J.M.; Liechty, P.G.; Wang, W.; Gaston, S.; Braz, E.; Karrasch, M.; Nabors, L.B.; Markiewicz, M.; Lakeman, A.D.; Palmer, C.A.; Parker, J.N.; Whitley, R.J.; Gillespie, G.Y. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther, 2009, 17, 199-207.
65. Kemeny, N.; Brown, K.; Covey, A.; Kim, T.; Bhargava, A.; Brody, L.; Guilfoyle, B.; Haag, N.P.; Karrasch, M.; Glasschroeder, B.; Knoll, A.; Getrajdman, G.; Kowal, K.J.; Jarnagin, W.R.; Fong, Y. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther, 2006, 17, 1214-1224.
66. Fong, Y.; Kim, T.; Bhargava, A.; Schwartz, L.; Brown, K.; Brody, L.; Covey, A.; Karrasch, M.; Getrajdman, G.; Mescheder, A.; Jarnagin, W.; Kemeny, N. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther, 2009, 17, 389-394.
67. Senzer, N.N.; Kaufman, H.L.; Amatruda, T.; Nemunaitis, M.; Reid, T.; Daniels, G.; Gonzalez, R.; Glaspy, J.; Whitman, E.; Harrington, K.; Goldsweig, H.; Marshall, T.; Love, C.; Coffin, R.; Nemunaitis, J.J. Phase II clinical trial of a granulocyte-macrophage colonystimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol, 2009, 27, 5763-5771.
68. Kaufman, H.L.; Kim, D.W.; Deraffele, G.; Mitcham, J.; Coffin, R.S.; Kim-Schulze, S. Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma. Ann Surg Oncol, 2009.
69. Chiocca, E.A. The host response to cancer virotherapy. Curr Opin Mol Ther, 2008, 10, 38-45.
70. Humphrey, W.; Dalke, A.; Schulten, K. VMD: visual molecular dynamics. J Mol Graph, 1996, 14, 33-38, 27-38.
71. Carfi, A.; Willis, S.H.; Whitbeck, J.C.; Krummenacher, C.; Cohen, G.H.; Eisenberg, R.J.; Wiley, D.C. Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol Cell, 2001, 8, 169-179.